The Potential Role of Targeting the Leptin Receptor As a Treatment for Breast Cancer in the Context of Hyperleptinemia: a Literature Review

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 2024 Nov 20

PMID 39565396

Authors

Abbas S Neamah

Al-Hassan Soliman Wadan

Fadhel M Lafta

Doha El-Sayed Elakwa

Affiliations

Soon will be listed here.

Abstract

Since cancer is becoming a leading cause of death worldwide, efforts should be concentrated on understanding its underlying biological alterations that would be utilized in disease management, especially prevention strategies. Within this context, multiple bodies of evidence have highlighted leptin's practical and promising role, a peptide hormone extracted from adipose and fatty tissues with other adipokines, in promoting the proliferation, migration, and metastatic invasion of breast carcinoma cells. Excessive blood leptin levels and hyperleptinemia increase body fat content and stimulate appetite. Also, high leptin level is believed to be associated with several conditions, including overeating, emotional stress, inflammation, obesity, and gestational diabetes. It has been noted that when leptin has impaired signaling in CNS, causing the lack of its normal function in energy balance, it results in leptin resistance, leading to a rise in its concentration in peripheral tissues. Our research paper will shed highlighting on potentially targeting the leptin receptor and its cellular signaling in suppressing breast cancer progression.

References

Abd El-Jawad A, Ibrahim I, Zaki M, Elias T, Rasheed W, Amr K . The potential role of miR-27a and miR-320a in metabolic syndrome in obese Egyptian females. J Genet Eng Biotechnol. 2022; 20(1):75. PMC: 9120291. DOI: 10.1186/s43141-022-00348-x. View

Ahlin C, Lundgren C, Embretsen-Varro E, Jirstrom K, Blomqvist C, Fjallskog M . High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers. Breast Cancer Res Treat. 2017; 164(3):667-678. PMC: 5495873. DOI: 10.1007/s10549-017-4294-5. View

Alwan N . Breast Cancer Among Iraqi Women: Preliminary Findings From a Regional Comparative Breast Cancer Research Project. J Glob Oncol. 2017; 2(5):255-258. PMC: 5493264. DOI: 10.1200/JGO.2015.003087. View

Ando S, Barone I, Giordano C, Bonofiglio D, Catalano S . The Multifaceted Mechanism of Leptin Signaling within Tumor Microenvironment in Driving Breast Cancer Growth and Progression. Front Oncol. 2014; 4:340. PMC: 4245002. DOI: 10.3389/fonc.2014.00340. View

Ara T, DeClerck Y . Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer. 2010; 46(7):1223-31. PMC: 2917917. DOI: 10.1016/j.ejca.2010.02.026. View

Arsenic R, Lehmann A, Budczies J, Koch I, Prinzler J, Kleine-Tebbe A . Analysis of PIK3CA mutations in breast cancer subtypes. Appl Immunohistochem Mol Morphol. 2014; 22(1):50-6. DOI: 10.1097/pdm.0b013e318297afea. View

Badodekar N, Sharma A, Patil V, Telang G, Sharma R, Patil S . Angiogenesis induction in breast cancer: A paracrine paradigm. Cell Biochem Funct. 2021; 39(7):860-873. DOI: 10.1002/cbf.3663. View

Bagnato G, Leopizzi M, Urciuoli E, Peruzzi B . Nuclear Functions of the Tyrosine Kinase Src. Int J Mol Sci. 2020; 21(8). PMC: 7215861. DOI: 10.3390/ijms21082675. View

Banks W . Role of the blood-brain barrier in the evolution of feeding and cognition. Ann N Y Acad Sci. 2012; 1264:13-9. PMC: 3464352. DOI: 10.1111/j.1749-6632.2012.06568.x. View

10.

Baud V, Karin M . Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009; 8(1):33-40. PMC: 2729321. DOI: 10.1038/nrd2781. View

11.

Bertucci A, Bertucci F, Goncalves A . Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements. Cancers (Basel). 2023; 15(5). PMC: 10001361. DOI: 10.3390/cancers15051416. View

12.

Bocian-Jastrzebska A, Malczewska-Herman A, Kos-Kudla B . Role of Leptin and Adiponectin in Carcinogenesis. Cancers (Basel). 2023; 15(17). PMC: 10486522. DOI: 10.3390/cancers15174250. View

13.

Bollrath J, Phesse T, von Burstin V, Putoczki T, Bennecke M, Bateman T . gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell. 2009; 15(2):91-102. DOI: 10.1016/j.ccr.2009.01.002. View

14.

Brahmi M, Bally O, Eberst L, Cassier P . [Therapeutic targeting of Notch signaling in cancer]. Bull Cancer. 2017; 104(10):883-891. DOI: 10.1016/j.bulcan.2017.07.007. View

15.

Brakenhielm E, Veitonmaki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B . Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A. 2004; 101(8):2476-81. PMC: 356975. DOI: 10.1073/pnas.0308671100. View

16.

Brizzi M, Dentelli P, Pavan M, Rosso A, Gambino R, Grazia De Cesaris M . Diabetic LDL inhibits cell-cycle progression via STAT5B and p21(waf). J Clin Invest. 2002; 109(1):111-9. PMC: 150820. DOI: 10.1172/JCI13617. View

17.

Buday L, Vas V . Novel regulation of Ras proteins by direct tyrosine phosphorylation and dephosphorylation. Cancer Metastasis Rev. 2020; 39(4):1067-1073. PMC: 7680326. DOI: 10.1007/s10555-020-09918-2. View

18.

Samudio I, Safe S . Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements. J Biol Chem. 2001; 276(33):30853-61. DOI: 10.1074/jbc.M103339200. View

19.

Catalano S, Leggio A, Barone I, De Marco R, Gelsomino L, Campana A . A novel leptin antagonist peptide inhibits breast cancer growth in vitro and in vivo. J Cell Mol Med. 2015; 19(5):1122-32. PMC: 4420614. DOI: 10.1111/jcmm.12517. View

20.

Catalano S, Marsico S, Giordano C, Mauro L, Rizza P, Panno M . Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. J Biol Chem. 2003; 278(31):28668-76. DOI: 10.1074/jbc.M301695200. View